SEC Form 6-K filed by HUTCHMED (China) Limited

$HCM
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $HCM alert in real time by email
6-K 1 hcm-20250314x6k.htm 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2025

Commission File Number: 001-37710


HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)


48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F               Form 40-F  


HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX

Exhibit No.

    

Description

Exhibit 99.1

Announcement relating to vesting of awards under the Long Term Incentive Plan

Exhibit 99.2

Overseas Announcement relating to adoption of the 2025 Long Term Incentive Plan

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HUTCHMED (CHINA) LIMITED

By:

/s/ Johnny Cheng

Name:

Johnny Cheng

Title:

Chief Financial Officer

Date: March 14, 2025

3


Get the next $HCM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HCM

DatePrice TargetRatingAnalyst
11/24/2023Hold → Buy
Deutsche Bank
5/4/2022Buy → Hold
Deutsche Bank
9/22/2021$46.00Buy → Neutral
Goldman
8/3/2021$52.00Buy
Jefferies
More analyst ratings

$HCM
Press Releases

Fastest customizable press release news feed in the world

See more
  • HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

    — First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED's fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application ("NDA") for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory ("R/R") follicular lymphoma ("FL") with EZH2 mutation who have received at least two prior systemic therapies.  This approval follows the priority review status by the National Medical Products Administration ("

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors of the Company for more than eight years, have informed the Company that they would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 13, 2025 ("AGM"). Consequently, both will cease to be Independent Non-executive Directors of the Company at the conclusion of the AGM. Upon their retirement, they will also step down from th

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

    — SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting — — Long-term survival benefit and safety observed in savolitinib Phase IIIb study in METex14 NSCLC — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED, savolitinib and surufatinib, will be presented at the European Lung Cancer Congress (ELCC) 2025, tak

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HCM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HCM
SEC Filings

See more

$HCM
Leadership Updates

Live Leadership Updates

See more
  • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications and water. He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison group, which

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HCM
Financials

Live finance-specific insights

See more
  • HUTCHMED to Announce 2024 Final Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025. In addition to the usual English webcast, there will also be a Chin

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

    — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to divest its 45% equity interest in Shang

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HUTCHMED to Announce 2024 Half-Year Financial Results

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT /

    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HCM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more